Coe F, Misra V, McCabe Y, Adderley H, et al. Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 2021 Nov 29. pii: 10.1007/s10549-021-06438.
PMID: 34843027